Atle Fretheim and his colleagues from the Norwegian Directorate for Health and Social Affairs estimated the potential annual savings for six countries if thiazides were prescribed whenever there was no reason to use an alternative. The savings could be huge: Canada - US$13.8m, France - US$37.4m, Germany - US$72.2m, Norway - US$10.7m, UK - US$119.7m and US - US$433.6m.

"Our calculations are based on conservative estimates. The potential for saving is likely to be considerably higher, and may be over US$1billion per year in the US," write the researchers.

To produce these estimates, the researchers used sales, prescription and survey data to estimate the number of people in each country that were being treated for high blood pressure, and the proportion of those that were taking thiazides. The proportion varied between countries from 12% to 40%. Previously published research suggests that thiazides could be used effectively in at least 45% of all cases. Armed with this information, the researchers worked out the potential annual cost savings to health services. They calculated the costs of increasing thiazide usage to its limit, and the resulting cost reductions of other treatments, assuming these reductions would be distributed evenly across those treatments.

All clinical guidelines recommend thiazides as a first choice drug for treating uncomplicated high blood pressure. This is because no drug to treat high blood pressure has been identified as being clearly superior to the others, and the evidence that thiazides reduce the risk of stroke and heart disease is strong. Thiazides are also amongst the best tolerated drugs, and are by far
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
7-Sep-2003